Business Context and Reporting Period
Company: ENDRA Life Sciences Inc. (NDRA)
Filing Type: Form 10-Q (Unaudited)
Period: Three months ended March 31, 2026
Business Overview: ENDRA is developing the TAEUS platform, a medical device for non-invasive liver fat measurement to support metabolic disease management and GLP-1 drug eligibility. In 2025, the company expanded its strategy to include a Digital Asset Treasury (DAT) initiative, investing in decentralized finance assets (primarily HYPE tokens) to generate non-dilutive returns.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,311,433) | $(1,036,330) |
| Operating Loss | $(2,173,748) | $(1,469,282) |
| Cash and Cash Equivalents (End of Period) | $356,462 | $2,064,874 |
| Net Cash Used in Operating Activities | $(1,119,650) | $(1,293,129) |
| Total Assets | $3,438,182 | $3,853,797 |
| Working Capital | $(298,774) | $(Negative) |
| Digital Assets (Fair Value) | $2,430,781 | $2,009,960 |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by $704,466 (48%) to $2.17 million. This was driven by a 60% increase in General and Administrative (G&A) expenses to $1.39 million, largely due to $574,451 in stock-based compensation. Research and Development (R&D) expenses rose 47% to $776,410 as the company focused on clinical trials and commercialization. Conversely, Sales and Marketing expenses dropped 94% to $4,278 due to restructuring and reduced headcount.
- Other Income: Total other income increased to $862,315 from $432,952. This was primarily due to an unrealized gain of $738,177 and a realized gain of $121,584 on digital assets, offset by a minor loss on warrant liability changes.
- Liquidity: Cash balances decreased by approximately $406,000 during the quarter. The company utilized $450,000 in proceeds from the sale of digital assets and $263,747 from common stock issuances to offset operating cash burn.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern. With an accumulated deficit of $111.8 million and a negative working capital position, the company requires additional financing to fund operations.
- Strategic Alternatives: In March 2026, the Board initiated a review of strategic alternatives, including mergers, business combinations, asset sales, or the sale of the company.
- Nasdaq Compliance: On April 20, 2026, Nasdaq notified the company of non-compliance with the Minimum Stockholders' Equity Requirement ($2.26 million reported equity vs. required threshold). The company has requested a hearing to avoid delisting but cannot guarantee compliance will be regained.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, citing a material weakness due to insufficient accounting personnel to segregate duties.
- Digital Asset Strategy: The company continues to hold and stake HYPE tokens. While this generated significant non-cash gains in Q1 2026, the strategy exposes the company to market volatility and regulatory risks.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $356,462 cash balance against the current burn rate of ~$1.1 million per quarter.
- Nasdaq Status: Monitor the outcome of the Nasdaq hearing regarding the Minimum Stockholders' Equity deficiency.
- Strategic Review: Track the progress of the Board's review of strategic alternatives (mergers/sales) announced in March 2026.
- Digital Asset Valuation: Assess the volatility risk of the $2.43 million digital asset holding, which significantly impacts reported equity and net income but may not be liquidable at fair value in a distressed scenario.
- Financing Plans: Confirm the availability and terms of the At-The-Market (ATM) program with Lucid Capital Markets, noting limitations due to public float rules.